BPC-157 is a 15-amino-acid peptide first described by researchers in 1993, and most research on it has been done in rodents and laboratory models.1 It is not an FDA-approved drug, and FDA’s 2026 evaluation found no approved medicine containing it in any country it searched.1 Published human data are limited to a few small, short studies. FDA concluded they do not show that it works for the one use it evaluated, ulcerative colitis, and are not enough to describe its safety.1 FDA staff recommended against adding BPC-157 to the list of substances pharmacies may use in compounding, but an October 2026 HHS draft policy lists it among six peptides that licensed pharmacies may compound under set conditions without federal enforcement action while FDA’s rulemaking continues.1,7,8
BPC-157 at a glance
What it is
A 15-amino-acid peptide. FDA describes it as a fragment of a protein originally isolated from human gastric juice.1
FDA status
Not FDA-approved. FDA staff recommended in May 2026 against adding it to the 503A compounding list, and FDA has not issued a final rule. Under an October 30, 2026 HHS draft enforcement-discretion policy, BPC-157 is one of six listed peptides that licensed pharmacies and physicians may compound under set conditions without federal enforcement action.1,7,8
Human evidence
A few small, short human studies, including one randomized ulcerative colitis study reported only as a meeting abstract. Two registered trials had no posted results in the cited registry records.1,3,5
Sport status
FDA’s briefing notes that BPC-157 is on the World Anti-Doping Agency’s prohibited list under non-approved substances (S0), as FDA checked in December 2025.1
Evidence strength
Limited human data. The only cited human studies are small, short, uncontrolled, or incompletely reported, such as case series, pilot studies, or trials published only as a conference abstract whose methods and results cannot be checked. How this label is assigned
What is BPC-157?
BPC-157 is a peptide made of 15 amino acids. FDA’s briefing describes it as a fragment of a larger protein, called body protection compound, that was originally isolated from human gastric juice. It is also known as bepecin or PL 14736.1
Researchers first described BPC-157 in 1993 and have studied it mainly for proposed protective and healing effects in animals. FDA could not determine how long it has been used in pharmacy compounding.1
FDA found BPC-157 marketed in the United States as an ingredient in dietary supplement products, and found that websites promoting it most often mention digestive uses.1
How is BPC-157 thought to work?
How BPC-157 works has not been established. FDA’s briefing states that its molecular targets have not been identified and that its mechanisms of action remain poorly understood.1
Based on animal and laboratory studies, researchers have proposed that it may increase growth-factor signaling, reduce inflammatory signals, promote new blood-vessel formation, and raise nitric oxide production.1
FDA cautions that these animal findings should be interpreted carefully, because larger amounts did not produce consistently larger effects and the biological plausibility of the reported effects is hard to assess.1
What do human studies show?
FDA’s 2026 review identified five published human studies. All were small and short, and FDA found that their authors provided limited safety information.1
The only randomized, placebo-controlled study FDA found tested a BPC-157 enema for two weeks in 53 people with ulcerative colitis. It was reported only as a 2005 meeting abstract, and FDA concluded its data were inadequate to support efficacy or safety.1
No serious adverse events appear to have been reported in these studies, but FDA notes that safety monitoring was unclear for most of them. FDA found no human studies using the oral, under-the-skin, nasal or skin routes proposed for compounded products.1
FDA’s adverse-event reports include injection-site reactions, shortness of breath, and darkening of the skin and gums after BPC-157 use, but FDA could not determine whether BPC-157 caused them.1
Two newer trials are registered: a Phase 2 hamstring-strain trial and a Phase 1 rotator cuff study. Neither had posted results in the cited registry records.3,5
What the evidence base contains
Small, short, or incompletely reported human study One randomized, placebo-controlled study of a BPC-157 enema in 53 people with ulcerative colitis, reported only as a 2005 meeting abstract. FDA found its reported details inadequate to support efficacy or safety conclusions.1
Small, short, or incompletely reported human study Four other small human reports listed by FDA: enema studies in healthy volunteers, knee-pain injections in 17 people, bladder injections in 12 people with interstitial cystitis, and an intravenous safety pilot in two healthy adults.1
Registered trial without results A randomized Phase 2 trial in adults with an acute hamstring strain, first posted in February 2026 as recruiting, with no results posted.3
Registered trial without results A Phase 1 study in rotator cuff tears, listed as not yet recruiting in its September 3, 2026 registry record.5
Animal or laboratory research Most published research reports effects in rodent and laboratory models, including gut, liver, tendon and nerve injury models.1
No. FDA’s May 2026 evaluation states that BPC-157 is not a component of any FDA-approved drug and that there is no United States Pharmacopeia monograph for it.1
Under section 503A of the federal drug law, the list of bulk substances that pharmacies can use in compounding, known as the 503A bulks list, is being developed through FDA rulemaking.7
FDA staff evaluated BPC-157 for that list for ulcerative colitis and recommended against adding it. They cited poor chemical characterization, limited safety information, a risk of immune reactions, insufficient evidence of effectiveness, and existing FDA-approved treatments for ulcerative colitis.1
FDA’s compounding safety-risk page, last updated April 22, 2026, lists BPC-157 among substances whose nominations were withdrawn and says FDA lacks enough information to know whether it would cause harm in people.2
FDA’s Pharmacy Compounding Advisory Committee discussed BPC-157 at its July 23–24, 2026 meeting. HHS’s policy document states that the committee voted in favor of including it, while FDA’s drug-review center had recommended against listing either form. FDA’s own meeting page, last updated August 6, 2026, lists no vote record.1,4,8
On October 30, 2026, HHS published notice of a draft policy saying it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians compounding with the peptide substances listed in the policy’s appendix while the 503A list is developed. HHS says the policy is not binding and may be revisited if safety or quality problems arise.7
Appendix A of the policy lists six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. The policy applies only when its conditions are met, including a patient-specific prescription, a single listed active ingredient, bulk substance from an FDA-registered facility with a certificate of analysis, and reporting of serious adverse events to FDA.8
The policy does not make BPC-157 an FDA-approved drug. HHS notes that FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed.8
Timeline
Researchers first describe BPC-157 in the scientific literature.1
A Federal Register notice announces the July advisory-committee meeting that will discuss BPC-157 and opens a public comment docket.6
FDA’s compounding safety-risk page, as last updated, lists BPC-157 among withdrawn nominations and describes immune-reaction and characterization concerns.2
FDA staff date their evaluation recommending that BPC-157 not be added to the 503A bulks list.1
HHS publishes notice of a draft enforcement-discretion policy whose Appendix A lists BPC-157 among six peptide substances used in compounding.7,8
What is still unknown?
Whether BPC-157 benefits people for any condition: none of the human studies FDA identified was a fully reported controlled trial.1
Its safety with repeated or long-term use, and how much reaches the bloodstream after oral, injected, nasal or skin use, have not been established in people.1
What is actually in products sold under the name: FDA notes that the free base and acetate forms are distinct substances and that inconsistent naming is a safety risk.1
Whether FDA’s rulemaking will add BPC-157 to the 503A list, and how long the October 2026 HHS interim policy will remain in place, remained unresolved in the sources reviewed through November 14, 2026.1,7,8
Compare and browse
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Records, reviews and history
Everything PeptideScanner has collected for BPC-157: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for BPC-157 are the records PeptideScanner has selected and published, not every registration or paper about BPC-157. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.
Status brief and reviewed-evidence summary
Evidence questions
Start with the question you have
Open the cited status, reviewed human evidence, unresolved limits, or profile changes.
Not an FDA-approved drug. FDA staff recommended in May 2026 against adding BPC-157 to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists BPC-157 among six peptides that may be compounded under set conditions without federal enforcement action; it does not make BPC-157 an FDA-approved drug.↗↗↗↗
Review source snapshots checked August 18, 2026 · Integrity checked August 19, 2026.
A bounded review of one human safety pilot, one literature-and-patent review, and one current human trial protocol.↗↗↗
What the reviewed sources report
This source set contains a two-person uncontrolled safety pilot, a narrative review dominated by preclinical research, and a recruiting Phase 2 protocol with no posted results. It does not establish human efficacy.↗↗↗
What remains unresolved?
Do adequately powered controlled human trials reproduce any claimed benefit and characterize harms over meaningful follow-up?↗↗
A bounded review of one human safety pilot, one literature-and-patent review, and one current human trial protocol.213
Bottom line from this bounded source set
This source set contains a two-person uncontrolled safety pilot, a narrative review dominated by preclinical research, and a recruiting Phase 2 protocol with no posted results. It does not establish human efficacy.213
Reviewed study record
Two-person human safety pilot
Design
An IRB-approved, uncontrolled pilot measured selected laboratory values, vital signs, and participant-reported side effects over a short observation window.2
Population
Two healthy adults at one private clinic participated; both had previously received BPC-157.2
Outcomes reported
The authors reported no measurable changes in the tested biomarkers and no participant-reported side effects during the observation window.2
Limitations
Two previously exposed participants, no comparator, one site, and short follow-up cannot establish general safety or any treatment effect.2
Reviewed study record
Current hamstring-strain protocol
Design
A randomized, parallel, quadruple-masked Phase 2 protocol is listed as recruiting. The registry currently posts a study plan, not results.3
Population
The protocol estimates 120 adults with an acute MRI-confirmed grade II hamstring strain.3
Outcomes reported
Return to unrestricted sport and change in MRI-assessed injury volume are registered primary outcomes; no outcome data are posted.3
Limitations
Recruitment status and planned outcomes do not demonstrate completion, safety, or effectiveness.3
Reviewed study record
Review-level context
Design
A narrative literature-and-patent review summarizes proposed mechanisms, preclinical models, patents, toxicity discussion, and limited clinical context.1
Population
The reviewed activity is primarily drawn from preclinical models rather than controlled human trials.1
Outcomes reported
The review describes favorable findings reported across preclinical models while stating that comprehensive human clinical studies are insufficient.1
Limitations
Narrative synthesis and preclinical findings cannot substitute for controlled human evidence, and the review does not establish clinical benefit.1
No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.3390/ph18020185. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
FDA evaluated BPC-157 free base and acetate separately for ulcerative colitis. The briefing recommended against their inclusion on the 503A bulks list. It explicitly precedes a final agency determination; this summary does not report a final ruling. FDA PDF pp. 1, 5, 8, 9 ↗FDA PDF pp. 43, 44, 45, 46, 47 ↗
More findings and the sources behind them
Selected FDA advisory-briefing sections, not a final agency ruling. The source date identifies the committee meeting (July 23–24 for the 2026 packages), not a new approval or final decision.
The human trial evidence was limited
FDA identified a 53-participant, two-week randomized study reported only in a meeting abstract. Missing endpoint, eligibility, statistical and follow-up details prevented it from supporting efficacy and safety conclusions for ulcerative colitis. FDA PDF pp. 25, 27, 28, 29 ↗
Formulation and duration limit extrapolation
The reviewed trial used a rectal enema, not the nominated suppository. FDA found no ulcerative-colitis studies using the proposed oral, subcutaneous, nasal or transdermal routes. These findings cannot establish effectiveness for tendon or sports injuries. FDA PDF pp. 1, 5, 8, 9 ↗FDA PDF pp. 25, 27, 28, 29 ↗
Safety remains inadequately characterized
FDA described insufficient clinical safety information, limited long-term data and concerns involving peptide impurities, aggregation and immune responses. Its adverse-event reports could not establish causality. FDA PDF pp. 43, 44, 45, 46, 47 ↗
Rectal-enema findings do not validate other formulations
The briefing distinguishes the studied rectal enema from the nominated suppository and other routes. FDA found no human pharmacokinetic data for oral, subcutaneous, nasal or transdermal administration in its reviewed sources. FDA PDF pp. 27, 40 ↗
Assay experiments are not human treatment studies
FDA identified laboratory plasma-metabolism reports used for anti-doping detection in which BPC-157 was not administered to people. Such work must not be counted as a clinical exposure study. FDA PDF pp. 40 ↗
Reported adverse events cannot establish causation or incidence
FDA discussed injection-related reports but noted incomplete information and concomitant substances. Those reports neither prove that BPC-157 caused each event nor establish a reliable adverse-event rate. FDA PDF pp. 41, 44 ↗
What remains to be checked
Check subsequent advisory records and any final FDA action separately from the staff briefing.
Retrieve and appraise the original human reports and proposed formulation or route; agency search findings are dated and do not establish a complete worldwide literature review.
Source dates and review coverage
PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.
Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.
Catalog-name and calibrated alias discovery for human evidence review. Complete query retrieval is separate from clinical eligibility, study-family linkage and appraisal.
219 retrieved · 2 included · 0 excluded · 217 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
"BPC-157"[Title/Abstract] OR "BPC 157"[Title/Abstract] OR "Body protection compound 157"[Title/Abstract]
Retrieved IDs completely represent this query response, not all relevant literature. Additional aliases, references and non-PubMed sources require separate searches.
Unscreened records may include animal or cell experiments, reviews, secondary analyses, mixtures, protocols and unrelated name matches.
Study-family mappings use available declared registry IDs; unresolved mappings do not create independent trial counts. Full-text, corrections and registry comparison remain separate work.
Showing 25 of 219 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
PubMed 40131143 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: bpc-157-PMID40131143-registry-linkage-unresolved.Bibliographic record recheck · 2026-09-15
The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗
PubMed 40005999 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: bpc-157-PMID40005999-registry-linkage-unresolved.Bibliographic record recheck · 2026-09-15
The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗
PubMed 42667535 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42635865 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42578445 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42555375 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42542926 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42533460 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42385164 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42356491 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42328738 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42278509 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42222211 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42204242 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42198317 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42160466 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42123471 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42123221 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42021992 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 41966639 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 41901308 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 41898733 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 41832718 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 41754849 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 41754776 — not screened: Name-query match awaiting clinical eligibility screening.
FDA search
Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov search
ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.
4 retrieved · 0 included · 0 excluded · 4 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
"BPC-157" OR "Body protection compound 157" OR "BPC 157"
Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
Other registries, unregistered studies and additional aliases remain outside this query.
Showing 4 of 4 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov NCT07437547 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07752381 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT02637284 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07803250 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
Explore status sources, recent additions, and coverage gaps
Living status brief
What is the current status of BPC-157?
Not an FDA-approved drug. FDA staff recommended in May 2026 against adding BPC-157 to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists BPC-157 among six peptides that may be compounded under set conditions without federal enforcement action; it does not make BPC-157 an FDA-approved drug.↗↗↗↗
The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.
PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
1 of 2 selected trial records include at least one phase value; 1 of 2 include a status value in the retained structured contract.
PhasesPhase 1 1
Status at observationNot yet recruiting 1
A phase value is unavailable here for 1 selected record; this is not counted as “no phase.”
A status value is unavailable here for 1 selected record; this is not counted as a trial status.
PubMed bibliography
Publication composition
24 of 49 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Publication typesJournal Article 24Review 9Research Support, Non-U.S. Gov't 3Comparative Study 2Validation Study 1
Bibliography fields unavailable here for 25 selected records; the records remain visible as metadata observations.
Regulatory and publication surfaces
What is structurally connected?
Drugs@FDA applications
0
FDA Federal Register documents
1
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
53
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Profile publication history and record countsSource records by collection · 53 dated records
We added a plain-language reader guide with cited answers, re-checked FDA’s BPC-157 records, added a second registered trial, and added HHS’s October 30, 2026 draft enforcement-discretion policy, which lists BPC-157. FDA has not issued a final 503A rule.
PubMed lists PMID 42794771 in International journal of molecular sciences as Journal Article, Review, with publication-date metadata of 2026-09-19 (day precision). PeptideScanner associated the retained record with the identity slug bpc-157. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT07803250 at 2026-09-09T19:17:17.410Z. Its registry update date was 2026-09-03, and PeptideScanner's reviewed identity mapping was bpc-157.
Selected records span November 16, 2017 to September 29, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
PubMed lists PMID 42794771 in International journal of molecular sciences as Journal Article, Review, with publication-date metadata of 2026-09-19 (day precision). PeptideScanner associated the retained record with the identity slug bpc-157. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PeptideScanner retained ClinicalTrials.gov record NCT07803250 at 2026-09-09T19:17:17.410Z. Its registry update date was 2026-09-03, and PeptideScanner's reviewed identity mapping was bpc-157.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42555375 at 2026-08-10T10:49:12.992Z. PubMed recorded a metadata revision date of 2026-08-05 and an Entrez history date of 2026-08-05. PeptideScanner associated this retained record with the identity slug bpc-157. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 40756949 at 2026-08-10T10:49:06.956Z. PubMed recorded a metadata revision date of 2026-08-01 and an Entrez history date of 2025-08-04. PeptideScanner associated this retained record with the identity slug bpc-157. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42278509 at 2026-08-10T18:13:52.250Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-12. PeptideScanner associated this retained record with the identity slug bpc-157. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42356491 at 2026-08-10T18:13:53.763Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-26. PeptideScanner associated this retained record with the identity slug bpc-157. These dates describe PubMed metadata history, not the article's original publication date.↗
FDA convened its Pharmacy Compounding Advisory Committee on July 23-24, 2026, to discuss free-base and acetate bulk drug substances across seven peptide-related groups.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41898733 at 2026-08-10T18:13:46.758Z. PubMed recorded a metadata revision date of 2026-07-13 and an Entrez history date of 2026-03-28. PeptideScanner associated this retained record with the identity slug bpc-157. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42385164 at 2026-07-30T16:11:44.943Z. PubMed recorded a metadata revision date of 2026-07-01 and an Entrez history date of 2026-07-01. PeptideScanner associated this retained record with the identity slug bpc-157. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 40789979 at 2026-07-30T16:14:11.079Z. PubMed recorded a metadata revision date of 2026-06-26 and an Entrez history date of 2025-08-11. PeptideScanner associated this retained record with the identity slug bpc-157. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42198317 at 2026-07-30T16:20:45.939Z. PubMed recorded a metadata revision date of 2026-05-29 and an Entrez history date of 2026-05-27. PeptideScanner associated this retained record with the identity slug bpc-157. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42123221 at 2026-07-30T16:20:45.661Z. PubMed recorded a metadata revision date of 2026-05-15 and an Entrez history date of 2026-05-13. PeptideScanner associated this retained record with the identity slug bpc-157. These dates describe PubMed metadata history, not the article's original publication date.↗